Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Phosphatidylinositol 3-kinase α (PI3Kα) is a crucial target in anticancer drug development.
• The oncogenic H1047R mutation in PI3Kα is prevalent in various tumors and can increase kinase activity.
• Understanding structural changes induced by this mutation is vital for designing effective therapies.

Purpose of the Study:

• To investigate the impact of the H1047R mutation on PI3Kα structure and inhibitor binding.
• To explore the potential for designing isoform- and mutant-specific PI3K inhibitors.
• To elucidate the molecular basis for the activity and selectivity of existing PI3K inhibitors.

Main Methods:

• Molecular docking of 33 PI3K inhibitors against wild-type PI3Kα, H1047R mutant PI3Kα, and PI3Kγ.
• Molecular dynamics simulations to generate flexible protein conformations.
• Analysis of ligand-protein interactions, including hydrogen bonds and hydrophobic interactions.

Main Results:

• Identified specific amino acid residues (Gln859, Ser854, Tyr836, Ser774) with conformational differences between wild-type and H1047R mutant PI3Kα.
• These differences can be exploited to design dual-acting inhibitors for both wild-type and mutant PI3Kα.
• Observed that interactions with Ser806 in PI3Kγ may enhance γ-isoform-specific inhibition.

Conclusions:

• Conformational variations in PI3Kα due to the H1047R mutation offer opportunities for targeted drug design.
• Structural and size disparities in activation and hydrophobic domains can guide the development of isoform- and mutant-specific inhibitors.
• The study provides a mechanistic basis for PI3K inhibitor activity and selectivity, aligning with experimental data.